Last reviewed · How we verify
NCT04509440
Efficacy of Neural Prolotherapy for Treatment of Anserine Bursitis "NPCAB"
NA trial testing isotonic dextrose 5% in water (D5W) solution in Anserine Bursitis in 43 participants. Completed in 30 October 2019.
30 October 2019
Quick facts
| Lead sponsor | University of Alexandria |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 1 May 2018 |
| Primary completion | 30 October 2019 |
| Estimated completion | 30 October 2019 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- isotonic dextrose 5% in water (D5W) solution — full drug profile →
- corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )
Conditions studied
- Anserine Bursitis — all drugs for Anserine Bursitis →
Sponsor
University of Alexandria
Who can join
Adults 18 to 70, any sex, with Anserine Bursitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Anserine bursitis is a common etiology of medial knee pain. It could be severe enough to limit the patient's functional abilities with affection of the quality of life. The etiology of AB is unknown. It could be bursitis, tendinitis or other unknown etiology. The treatment of AB includes conservative and surgical treatment. Conservative treatment consists of non-pharmacologic treatment and pharmacologic treatment. Local corticosteroid injection is a treatment for refractory chronic anserine bursitis. Neural prolotherapy is the subcutaneous perineural injection of isotonic dextrose 5% in water solution at the fascial penetration point of the sensory nerve where it reaches the subcutaneous plane and along its course. It can be used for the treatment of chronic anserine bursitis. This study aimed to determine the efficacy of neural prolotherapy subcutaneous perineural injection versus corticosteroid local soft tissue injection therapy for relieving pain and improvement of function among patients with chronic anserine bursitis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04509440
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Alexandria trials
Trials by the same sponsor.
- NCT03806439 — Post-surgical Delirium in Patients Undergoing Radical Cystectomy. · not yet recruiting
- NCT03806413 — Post-surgical Delirium in Patients Undergoing Open Heart Surgery. · not yet recruiting
- NCT04110132 — Postoperative Analgesia Using Ganglion Impar Block After Anal Surgery · NA · not yet recruiting
- NCT06529627 — GDF-8 Levels in ICSI Cycles · NA · completed
- NCT05306639 — Treatment of Monosymptomatic Nocturnal Enuresis · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04509440 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alexandria
- Last refreshed: 12 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04509440.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing